Navigation Links
Lenalidomide Gives New Hope To Chronic Lymphocytic Leukemia Patients

According to a phase II study conducted by Asher Chanan-Khan, MD, Department of Medicine, Roswell Park Cancer Institute (RPCI), patients treated with lenalidomide// for relapsed chronic lymphocytic leukemia (CLL) or diseases that no longer responded to chemotherapy have experienced a major response to the therapy. The results of this study were published in the December 1 issue of the Journal of Clinical Oncology.

"Chronic lymphocytic leukemia is the most common hematologic malignancy in the western hemisphere," according to Dr. Chanan-Khan, "and remains incurable." While several phase II studies have demonstrated improved clinical response to chemotherapy alone, or combined with the monoclonal antibody rituximab, relapse is inevitable and treatment options at that point are limited.

Lenalidomide is a novel immune modulating, non-chemotherapy, cancer drug that is chemically similar to thalidomide, but is more potent in the laboratory and appears to lack some of the more common side effects of thalidomide. Anticancer activity of this agent has been reported in various malignant disorders, including multiple myeloma and myelodysplastic syndrome.

In this phase II study – the first to report clinical activity of lenalidomide in patients with CLL – 45 patients with immunophenotypically diagnosed B-CLL were treated with a daily dose of 25 mg of lenalidomide. Major clinical responses were seen in 21 (47%) of the patients, with four achieving complete response and 17 achieving a partial response; all with a predictable and manageable safety profile. The most common side effects included fatigue, neutropenia and thrombocytopenia.

"Collectively, these data provide strong support for further pursuit of lenalidomide in confirmatory clinical studies that are now open at Roswell Park and other cancer centers in the country," notes Dr. Chanan-Khan.



Source-Eurekalert
SR
'"/>




Page: 1

Related medicine news :

1. Lenalidomide, Granted Approval by FDA to Join Multiple Myeloma Drugs
2. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
3. Gene Therapy Gives Hope For Patients With Muscular Dystrophy
4. Statins Gives New Hope for Increased Survival Rate of Heart Failure Patients
5. US Doctors Association Gives away $110,000 To NGO’
6. Woman In Coma Gives Birth To Daughter
7. Artificial Heart , Gives Hope For Patients Awaiting a Heart Transplant
8. New Eye Surgery Gives Hope To Short-Sighted
9. Jharkhand Gives Health industry status
10. WHO Gives Its Approval For Bird Flu Test Kit
11. FDA Gives Its Approval For Inhaler
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/24/2017)... ... March 24, 2017 , ... ... spark a conversation on the current obstacles facing infection prevention and offer strategies ... deaths caused by these infections. , The print component of “Fighting Infection” ...
(Date:3/24/2017)... Dallas, Texas (PRWEB) , ... March 24, 2017 , ... ... Budget Office score is invalid because it does not obey the rules Congress has ... million full-time equivalent jobs, which the GOP reform would restore. Yet, it estimates a ...
(Date:3/24/2017)... Sedona, Arizona (PRWEB) , ... March 24, 2017 ... ... Shamangelic Healing Center, Sedona, Arizona’s Premier Center for Shamanic Healing and Spiritual Awakening, ... Jorge Luis Delgado, June 9--24, 2017. This sacred and spiritual journey during ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... at the Advanced ERISA Benefit Claims Litigation seminar in Chicago, Illinois. She ... Record, The majority of cases litigated under ERISA involve claims for long-term disability ...
(Date:3/24/2017)... ... March 24, 2017 , ... Empower Brokerage, located in Southlake, ... leads programs. , In February, 2017, Empower Brokerage introduced their new “Performance Partners” ... designed to teach how to maximize their sales efforts, as well as how ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... 2017   The Accreditation Council for Medical ... in the pharmaceutical industry has appointed Dr. ... newly formed scientific advisory board. Dr. Chin will ... first ever medical affairs think tank within the ... the ACMA, please visit  www.medicalaffairsspecialist.org .  Connect ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The Deep Learning: Drug Discovery and Diagnostics Market, 2017-2035 ... market of deep learning solutions within the healthcare domain. Primarily driven ... a novel solution to generate relevant insights from medical data. ...
(Date:3/24/2017)... -- GenomeDx Biosciences today announced that six abstracts featuring Decipher ... Classifier tests will be presented at the 32 nd ... March 24 to 28, 2017 in London, ... Europe,s largest urological event showcasing the ... The abstract titled "Muscle invasive bladder cancer: ...
Breaking Medicine Technology: